AARD (Aardvark Therapeutics) Other Current Liabilities: $1.52 Mil (As of Mar. 2026)


AARD Aardvark Therapeutics Inc AARD
12 GF Score
Price $5.44
! 1 Warning Sign
View Full Analysis

What is Aardvark Therapeutics Other Current Liabilities?

Aardvark Therapeutics AARD -9.18% 12 Other Current Liabilities is $1.52 Mil as of Mar. 2026. GuruFocus rates AARD with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Aardvark Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $1.52 Mil.

Aardvark Therapeutics's quarterly other current liabilities increased from Sep. 2025 ($2.15 Mil) to Dec. 2025 ($2.91 Mil) but then declined from Dec. 2025 ($2.91 Mil) to Mar. 2026 ($1.52 Mil).

Aardvark Therapeutics's annual other current liabilities increased from Dec. 2023 ($0.04 Mil) to Dec. 2024 ($0.23 Mil) and increased from Dec. 2024 ($0.23 Mil) to Dec. 2025 ($2.91 Mil).

Aardvark Therapeutics Other Current Liabilities Related Terms

Aardvark Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Aardvark Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aardvark Therapeutics Other Current Liabilities Chart

Aardvark Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
0.05 0.04 0.23 2.91

Aardvark Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 1.38 2.15 2.91 1.52
AARD
12GF Score
Aardvark Therapeutics Inc AARD
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aardvark Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $1.52 Mil mean?
Aardvark Therapeutics (AARD) has a Other Current Liabilities of $1.52 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aardvark Therapeutics.
Is Aardvark Therapeutics' Other Current Liabilities too high?
Aardvark Therapeutics' current Other Current Liabilities is $1.52 Mil. Overall, Aardvark Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aardvark Therapeutics' Other Current Liabilities compare to KLRS and VANI?
Aardvark Therapeutics' Other Current Liabilities of $1.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aardvark Therapeutics. Aardvark Therapeutics's current Other Current Liabilities is $1.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aardvark Therapeutics stock overvalued right now?
Aardvark Therapeutics (AARD) has a current Other Current Liabilities of $1.52 Mil. The current Other Current Liabilities is $1.52 Mil. Aardvark Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Aardvark Therapeutics (AARD), the current Other Current Liabilities is $1.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aardvark Therapeutics Business Description

Address 4370 La Jolla Village Drive, Suite 1050, San Diego, CA, USA, 92122
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
12GF Score

Get the complete analysis for AARD

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.44
Price